370 related articles for article (PubMed ID: 30846679)
1. Natural history of multiple myeloma with de novo del(17p).
Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Dispenzieri A; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
Blood Cancer J; 2019 Mar; 9(3):32. PubMed ID: 30846679
[TBL] [Abstract][Full Text] [Related]
2. Impact of acquired del(17p) in multiple myeloma.
Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
Blood Adv; 2019 Jul; 3(13):1930-1938. PubMed ID: 31248884
[TBL] [Abstract][Full Text] [Related]
3. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
Merz M; Hielscher T; Seckinger A; Hose D; Mai EK; Raab MS; Goldschmidt H; Jauch A; Hillengass J
Am J Hematol; 2016 Nov; 91(11):E473-E477. PubMed ID: 27508939
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
5. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
[No Abstract] [Full Text] [Related]
6. Survival analysis of transplant-eligible newly-diagnosed multiple myeloma patients harboring t(4;14), t(14;16), and/or del(17p) in the real-world setting.
Garrido D; Slavutsky I; Riva E;
Curr Probl Cancer; 2023 Feb; 47(1):100916. PubMed ID: 36473780
[TBL] [Abstract][Full Text] [Related]
7. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
Liu Y; Ke XY; Wang J; Wang YF; Dong F; Tian L; Wan W; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):802-806. PubMed ID: 28641639
[TBL] [Abstract][Full Text] [Related]
8. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
Boyd KD; Ross FM; Tapper WJ; Chiecchio L; Dagrada G; Konn ZJ; Gonzalez D; Walker BA; Hockley SL; Wardell CP; Gregory WM; Child JA; Jackson GH; Davies FE; Morgan GJ;
Genes Chromosomes Cancer; 2011 Oct; 50(10):765-74. PubMed ID: 21961181
[TBL] [Abstract][Full Text] [Related]
9. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
[TBL] [Abstract][Full Text] [Related]
10. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.
Wong SW; Hegenbart U; Palladini G; Shah GL; Landau HJ; Warner M; Toskic D; Jaccard A; Hansen T; Bladé J; Cibeira MT; Kastritis E; Dispenzieri A; Wechalekar A; Varga C; Schönland SO; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e493-e499. PubMed ID: 30104177
[TBL] [Abstract][Full Text] [Related]
11. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.
El-Ghammaz AM; Abdelwahed E
Ann Hematol; 2016 Aug; 95(8):1315-21. PubMed ID: 27184486
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
Avet-Loiseau H; Leleu X; Roussel M; Moreau P; Guerin-Charbonnel C; Caillot D; Marit G; Benboubker L; Voillat L; Mathiot C; Kolb B; Macro M; Campion L; Wetterwald M; Stoppa AM; Hulin C; Facon T; Attal M; Minvielle S; Harousseau JL
J Clin Oncol; 2010 Oct; 28(30):4630-4. PubMed ID: 20644101
[TBL] [Abstract][Full Text] [Related]
14. [Application of the Second Revision of the International Staging System (R2-ISS) in the prognostic assessment of newly diagnosed multiple myeloma].
Yan J; Zhou DM; Shao XY; Xu Y; Chen B
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):170-177. PubMed ID: 38604794
[No Abstract] [Full Text] [Related]
15. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.
Hebraud B; Magrangeas F; Cleynen A; Lauwers-Cances V; Chretien ML; Hulin C; Leleu X; Yon E; Marit G; Karlin L; Roussel M; Stoppa AM; Belhadj K; Voillat L; Garderet L; Macro M; Caillot D; Mohty M; Facon T; Moreau P; Attal M; Munshi N; Corre J; Minvielle S; Avet-Loiseau H
Blood; 2015 Mar; 125(13):2095-100. PubMed ID: 25636340
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805).
Kim K; Kim JS; Yoon SS; Yoon DH; Eom HS; Lee JJ; Yim HW; Park M; Lee H; Min CK;
Int J Hematol; 2022 Jul; 116(1):110-121. PubMed ID: 35543899
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
Dimopoulos MA; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Spencer A; Knop S; Bahlis NJ; Renner C; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel JF
Haematologica; 2015 Oct; 100(10):1327-33. PubMed ID: 26250580
[TBL] [Abstract][Full Text] [Related]
18. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.
Grzasko N; Hajek R; Hus M; Chocholska S; Morawska M; Giannopoulos K; Czarnocki K; Druzd-Sitek A; Pienkowska-Grela B; Rygier J; Usnarska-Zubkiewicz L; Dytfeld D; Kubicki T; Jurczyszyn A; Korpysz M; Dmoszynska A
Leuk Lymphoma; 2017 Sep; 58(9):1-15. PubMed ID: 28092996
[TBL] [Abstract][Full Text] [Related]
19. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]